Lentiviral Delivery of Proteins Using 2A Peptides IM KSE RL SSR. Analyzed the data: JDV WEC MG MH EW DD IM KSE SSR. Contributed reagents/materials/analysis tools: SSR. Wrote the paper: JDV WEC IM SSR. Conducted behavioral tests: WEC IM SSR. Editorial review: JDV WEC MG MH EW DD IM KSE RL SSR. References 1. Ali RR, Sarra GM, Stephens C, Alwis MD, Bainbridge JW, et al. (2000) Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat Genet 25: 306–310. 2. Pawlyk BS, Smith AJ, Buch PK, Adamian M, Hong DH, et al. (2005) Gene replacement therapy rescues photoreceptor degeneration in a murine model of Leber congenital amaurosis lacking RPGRIP. Invest Ophthalmol Vis Sci 46: 3039–3045. 3. Schlichtenbrede FC, da CL, Stephens C, Smith AJ, Georgiadis A, et al. (2003) Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene replacement therapy. J Gene Med 5: 757–764. 4. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, et al. (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358: 2231–2239. 5. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, et al. (2009) Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 20: 999–1004. 6. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Jr., Mingozzi F, et al. (2008) Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 358: 2240–2248. 7. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, et al. (2010) Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18: 643–650. 8. Marlhens F, Bareil C, Griffoin JM, Zrenner E, Amalric P, et al. (1997) Mutations in RPE65 cause Leber’s congenital amaurosis. Nat Genet 17: 139–141. 9. Redmond TM, Yu S, Lee E, Bok D, Hamasaki D, et al. (1998) Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet 20: 344–351. 10. Gao H, Hollyfield JG (1992) Aging of the human retina. Differential loss of neurons and retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 33: 1–17. 11. Dizhoor AM, Lowe DG, Olshevskaya EV, Laura RP, Hurley JB (1994) The human photoreceptor membrane guanylyl cyclase, RetGC, is present in outer segments and is regulated by calcium and a soluble activator. Neuron 12: 1345–1352. 12. Koch KW, Duda T, Sharma RK (2002) Photoreceptor specific guanylate cyclases in vertebrate phototransduction. Mol Cell Biochem 230: 97–106. 13. Perrault I, Rozet JM, Calvas P, Gerber S, Camuzat A, et al. (1996) Retinal- specific guanylate cyclase gene mutations in Leber’s congenital amaurosis. Nat Genet 14: 461–464. 14. Semple-Rowland SL, Lee NR, Van Hooser JP, Palczewski K, Baehr W (1998) A mutation in the photoreceptor guanylate cyclase gene causes the retinal degeneration chicken phenotype. Proc Natl Acad Sci U S A 95: 1271–1276. 15. Williams ML, Coleman JE, Haire SE, Aleman TS, Cideciyan AV, et al. (2006) Lentiviral expression of retinal guanylate cyclase-1 (RetGC1) restores vision in an avian model of childhood blindness. PLoS Med 3: e201. 16. Semple-Rowland SL, Coggin WE, Geesey M, Eccles KS, Abraham L, et al. (2010) Expression characteristics of dual-promoter lentiviral vectors targeting retinal photoreceptors and Muller cells. Mol Vis 16: 916–934. 17. Nethe M, Berkhout B, van der Kuyl AC (2005) Retroviral superinfection resistance. Retrovirology 2: 52. 18. Wong ET, Ngoi SM, Lee CG (2002) Improved co-expression of multiple genes in vectors containing internal ribosome entry sites (IRESes) from human genes. Gene Ther 9: 337–344. 19. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T (2000) IRES- dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 1: 376–382. 20. Semple-Rowland SL, Eccles KS, Humberstone EJ (2007) Targeted expression of two proteins in neural retina using self-inactivating, insulated lentiviral vectors carrying two internal independent promoters. Mol Vis 13: 2001–2011. 21. de Felipe P, Martin V, Cortes ML, Ryan M, Izquierdo M (1999) Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. Gene Ther 6: 198–208. 22. de Felipe P, Luke GA, Hughes LE, Gani D, Halpin C, et al. (2006) E unum pluribus: multiple proteins from a self-processing polyprotein. Trends Biotechnol 24: 68–75. 23. Ibrahimi A, Vande VG, Reumers V, Toelen J, Thiry I, et al. (2009) Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. Hum Gene Ther 20: 845–860. 24. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. (2004) Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol 22: 589–594. 25. Yu X, Zhan X, D’Costa J, Tanavde VM, Ye Z, et al. (2003) Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. Mol Ther 7: 827–838. 26. Gascon S, Paez-Gomez JA, az-Guerra M, Scheiffele P, Scholl FG (2008) Dual- promoter lentiviral vectors for constitutive and regulated gene expression in neurons. J Neurosci Methods 168: 104–112. 27. de Felipe P, Hughes LE, Ryan MD, Brown JD (2003) Co-translational, intraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2A peptide. J Biol Chem 278: 11441–11448. 28. de Felipe P, Luke GA, Brown JD, Ryan MD (2010) Inhibition of 2A-mediated ‘cleavage’ of certain artificial polyproteins bearing N-terminal signal sequences. Biotechnol J 5: 213–223. 29. Conley M, Fite KV (1980) Optokinetic nystagmus in the domestic pigeon. Effects of foveal lesions. Brain Behav Evol 17: 89–102. 30. Komenda JK, Fite KV (1983) Optokinetic nystagmus in progressive retinal degeneration. Behav Neurosci 97: 928–936. 31. Tauber ES, Atkin A (1968) Optomotor responses to monocular stimulation: relation to visual system organization. Science 160: 1365–1367. 32. Donnelly ML, Hughes LE, Luke G, Mendoza H, ten DE, et al. (2001) The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. J Gen Virol 82: 1027–1041. 33. Ryan MD, King AM, Thomas GP (1991) Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol 72(Pt 11): 2727–2732. 34. Ryan MD, Drew J (1994) Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J 13: 928–933. 35. Chinnasamy N, Shaffer J, Chinnasamy D (2009) Production of multicistronic HIV-1 based lentiviral vectors. Methods Mol Biol 515: 137–150. 36. de Felipe P, Ryan MD (2004) Targeting of proteins derived from self-processing polyproteins containing multiple signal sequences. Traffic 5: 616–626. 37. Rothwell DG, Crossley R, Bridgeman JS, Sheard V, Zhang Y, et al. (2010) Functional expression of secreted proteins from a bicistronic retroviral cassette based on FMDV 2A can be position-dependent. Hum Gene Ther 21: 1631–1637. 38. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, et al. (2005) Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23: 584–590. 39. Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, et al. (2008) Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther 15: 1411–1423. 40. Chumakov SP, Kravchenko JE, Prassolov VS, Frolova EI, Chumakov PM (2010) Efficient downregulation of multiple mRNA targets with a single shRNA- expressing lentiviral vector. Plasmid 63: 143–149. 41. Moumen A, Polomack L, Unge T, Veron M, Buc H, et al. (2003) Evidence for a mechanism of recombination during reverse transcription dependent on the structure of the acceptor RNA. J Biol Chem 278: 15973–15982. 42. Negroni M, Buc H (2001) Retroviral recombination: what drives the switch? Nat Rev Mol Cell Biol 2: 151–155. 43. Michalakis S, Muhlfriedel R, Tanimoto N, Krishnamoorthy V, Koch S, et al. (2010) Restoration of Cone Vision in the CNGA3(-/-) Mouse Model of Congenital Complete Lack of Cone Photoreceptor Function. Mol Ther 18: 2057–2063. 44. Pawlyk BS, Bulgakov OV, Liu X, Xu X, Adamian M, et al. (2010) Replacement gene therapy with a human RPGRIP1 sequence slows photoreceptor degeneration in a murine model of leber congenital amaurosis. Hum Gene Ther 21: 993–1004. 45. Provost E, Rhee J, Leach SD (2007) Viral 2A peptides allow expression of multiple proteins from a single ORF in transgenic zebrafish embryos. Genesis 45: 625–629. 46. Szymczak AL, Vignali KM, Vignali DA (2007) Generation of 2A Peptide-linked Multicistronic Vectors. In: Friedmann T, Rossi JJ, eds. Gene transfer: delivery and expression of DNA and RNA: a laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press. pp 137–147. 47. Coleman JE, Zhang Y, Brown GA, Semple-Rowland SL (2004) Cone cell survival and downregulation of GCAP1 protein in the retinas of GC1 knockout mice. Invest Ophthalmol Vis Sci 45: 3397–3403. PLoS ONE | www.plosone.org 12 May 2011 | Volume 6 | Issue 5 | e20553